Biology Reference
In-Depth Information
patients with end-stage renal disease. Results of a phase III multicenter clinical trial.
Ann Intern
Med
111: 992-1000
3 Sundal E, Kaeser U (1989) Correction of anaemia of chronic renal failure with recombinant
human erythropoietin: Safety and efficacy of one year's treatment in a European multicentre study
of 150 haemodialysis-dependent patients.
Nephrol Dial Transplant
4: 979-987
4 Breen CP, Macdougall IC (1999) Correction of epoetin-resistant megaloblastic anaemia following
vitamin B(12) and folate administration.
Nephron
83: 374-375
5 Van Wyck DB (1989) Iron deficiency in patients with dialysis-associated anemia during erythro-
poietin replacement therapy: strategies for assessment and management.
Semin Nephrol
9
(suppl. 2): 21-24
6 Macdougall IC (1994) Monitoring of iron status and iron supplementation in patients treated with
erythropoietin.
Curr Opin Nephrol Hypertens
3: 620-625
7 Fishbane S, Frei GL, Maesaka J (1995) Reduction in recombinant human erythropoietin doses by
the use of chronic intravenous iron supplementation.
Am J Kidney Dis
26: 41-46
8 Macdougall IC, Tucker B, Thompson J, Tomson CRV, Baker LRI, Raine AEG (1996) A random-
ized controlled study of iron supplementation in patients treated with erythropoietin.
Kidney Int
50: 1694-1699
9 Rao DS, Shih MS, Mohini R (1993) Effect of serum parathyroid hormone and bone marrow fibro-
sis on the response to erythropoietin in uremia.
N Engl J Med
328: 171-175
10Fluck S, McKane W, Cairns T, Fairchild V, Lawrence A, Lee J, Murray D, Polpitiye M, Palmer A,
Taube D (1999) Chloramine-induced haemolysis presenting as erythropoietin resistance.
Nephrol
Dial Transplant
14: 1687-1691
11 Teruel JL, Pascual J, Jimenez M, Liano F, Rivera M, Martinez J, Moya JL, Ortuno J (1991)
Hemodynamic changes in hemodialyzed patients during treatment with recombinant human ery-
thropoietin.
Nephron
58: 135-137
12 Macdougall IC, Lewis NP, Saunders MJ, Cochlin DL, Davies ME, Hutton RD, Fox KA, Coles
GA, Williams JD (1990) Long-term cardiorespiratory effects of amelioration of renal anaemia by
erythropoietin.
Lancet
335: 489-493
13Wizemann V, Kaufmann J, Kramer W (1992) Effect of erythropoietin on ischemia tolerance in
anemic hemodialysis patients with confirmed coronary artery disease.
Nephron
62: 161-165
14 Low-Friedrich I, Grutzmacher P, Marz W, Bergmann M, Schoeppe W (1991) Therapy with recom-
binant human erythropoietin reduces cardiac size and improves heart function in chronic
hemodialysis patients.
Am J Nephrol
11: 54-60
15 Pascual J, Teruel JL, Moya JL, Liano F, Jimenez-Mena M, Ortuno J (1991) Regression of left ven-
tricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodial-
ysis: A prospective study.
Clin Nephrol
35: 280-287
16 Silberberg J, Barre P, Prichard SS, Sniderman AD (1989) Impact of left ventricular hypertrophy
on survival in end-stage renal disease.
Kidney Int
36:286-290
17 Mayer G, Thum J, Cada EM, Stummvoll HK, Graf H (1988) Working capacity is increased fol-
lowing recombinant human erythropoietin treatment.
Kidney Int
34: 525-528
18 Vigano G, Benigni A, Mendogni D, Mingardi G, Mecca G, Remuzzi G (1991) Recombinant
human erythropoietin to correct uremic bleeding.
Am J Kidney Dis
18: 44-49
19 Macdougall IC, Davies ME, Hutton RD, Coles GA, Williams JD (1991) Rheological studies dur-
ing treatment of renal anaemia with recombinant human erythropoietin.
Br J Haematol
77:
550-558
20 Macdougall IC, Davies ME, Hallett I, Cochlin DL, Hutton RD, Coles GA, Williams JD (1991)
Coagulation studies and fistula blood flow during erythropoietin therapy in haemodialysis
patients.
Nephrol Dial Transplant
6: 862-867
21 Taylor JE, McLaren M, Henderson IS, Belch JJ, Stewart WK (1992) Prothrombotic effect of ery-
thropoietin in dialysis patients.
Nephrol Dial Transplant
7: 235-239
22 Huraib S, Gader AM, Al-Momen AK, Abu-Aisha H, Al-Wakeel J, Memon NA (1995) One-year
experience of very low doses of subcutaneous erythropoietin in continuous ambulatory peritoneal
dialysis and its effect on haemostasis.
Haemostasis
25: 299-304
23 Keown PA (1991) Quality of life in end-stage renal disease patients during recombinant human
erythropoietin therapy. The Canadian Erythropoietin Study Group.
Contrib Nephrol
88: 81-86
24 Marsh JT, Brown WS, Wolcott D, Carr CR, Harper R, Schweitzer SV, Nissenson AR (1991)
rHuEPO treatment improves brain and cognitive function of anemic dialysis patients.
Kidney Int
39: 155-163
